News

Article

Exscientia and GT Apeiron Form Strategic R&D Collaboration Agreement

Exscientia and GT Apeiron Therapeutics have entered into a strategic R&D oncology collaboration agreement.

Artificial intelligence (AI)-driven pharmatech company, Exscientia, and Shanghai-based oncology specialist, GT Apeiron Therapeutics, have entered into a strategic research and development collaboration agreement.

According to a July 21, 2021 press release, the oncology joint venture will involve leveraging Exscientia’s patient-centric AI-first capabilities and GT Apeiron’s expertise to speed up the discovery of multiple small-molecule therapeutic drug candidates, designed to selectively treat aberrant cell cycle-driven cancers. The ultimate goal of the collaboration will be to build a pipeline of cyclin-dependent kinase (CDK) novel therapies.

This joint venture expands upon previous work, where multiple selective CDK7 compounds were designed. These compounds have demonstrated consistent tumor responses in xenograft models, it was reported in the press release. Additionally, the CDK7 inhibitors were found to enhance tumor cell cytotoxicity and selectivity over immune cells in live primary tissue samples from ovarian cancer patients.

“Based on what they have already achieved, Exscientia is clearly the leader in AI-driven drug discovery, and we have witnessed this first-hand in our collaboration so far,” stated Mingxi Li, president of GT Apeiron Therapeutics, in the press release. “We have been incredibly impressed by the combined power of the AI design and use of patient data to optimize and select molecules that are more likely to give positive effects in the clinic. This joint venture is a significant step in building GT Apeiron’s valuable and robust pipeline of CDK inhibitor drugs and substantially accelerates our early-stage output and progression towards being a clinical-stage biotech company.”

“We are driven to bring drugs to market that make a difference for patients,” added Andrew Hopkins, CEO of Exscientia, in the press release. “Apeiron bring a focus and an expertise on the biological basis of multiple cancers and helps us to create better drugs for better outcomes in the clinic and beyond. This collaboration has already proven to be capable of delivering potential drug candidates with promising patient-relevant data, and we look forward to extending that into a portfolio of multiple clinical assets.”

Source: Exscientia

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content